Skip to main content

Table 4 Solicited Grade 3/4 toxicities (physician evaluation) by baseline KI and age group

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

   n (%) of patients with maximum Grade 3/4 toxicity  
Toxicity All patients treated (N = 516) Baseline KI ≥ 80% (N = 322) Baseline KI < 80% (N = 193) Age < 70 years (N = 329) Age ≥ 70 years (N = 187)
Any toxicity 123 (23.8) 56 (17.4) 67 (34.7) 87 (26.4) 36 ( 19.3)
Fatigue/asthenia 82 (15.9) 32 ( 9.9) 50 (25.9) 54 (16.4) 28 ( 15.0)
Neutropenia 45 ( 8.7) 21 ( 6.5) 24 (12.4) 30 ( 9.1) 15 ( 8.0)
Nausea 16 ( 3.1) 6 ( 1.9) 10 ( 5.2) 10 ( 3.0) 6 ( 3.2)
Febrile neutropenia 10 ( 1.9) 3 ( 0.9) 7 ( 3.6) 6 ( 1.8) 4 ( 2.1)
Rash/desquamation 7 ( 1.4) 6 ( 1.9) 1 ( 0.5) 4 ( 1.2) 3 ( 1.6)
Stomatitis/pharyngitis 7 ( 1.4) 3 ( 0.9) 4 ( 2.1) 3 ( 0.9) 4 ( 2.1)
Mucositis 5 ( 1.0) 1 ( 0.3) 4 ( 2.1) 3 ( 0.9) 2 ( 1.1)
Vomiting 5 ( 1.0) 2 ( 0.6) 3 ( 1.6) 4 ( 1.2) 1 ( 0.5)
Diarrhea 2 ( 0.4) 1 ( 0.3) 1 ( 0.5) 2 ( 0.6) 0 ( 0.0)
  1. KI Karnofsky Index, N = total number of patients, n = number of patients
\